Revenue Performance - Total revenues for the three months ended March 30, 2025, decreased by 3% to $692.8 million compared to $711.0 million for the same period in the prior year[90]. - Revenue from respiratory products accounted for 17% of total revenues for the three months ended March 30, 2025, down from 19% in the prior year, with COVID-19 related revenue decreasing from $50.2 million to $23.4 million[81]. - Labs revenue increased by 5% to $373.1 million, driven by growth in reagents, consumables, and services, while Point of Care revenue decreased by 8% to $170.8 million[89]. - Total revenues for North America decreased by 6% to $406.7 million for the three months ended March 30, 2025, compared to $433.9 million for the same period in 2024[104]. - EMEA segment reported a 5% increase in total revenues to $88.9 million, with Adjusted EBITDA rising 42% to $16.5 million[106]. - China total revenues decreased by 1% to $75.0 million, while Adjusted EBITDA increased by 12% to $29.3 million[108]. - Total revenues for the "Other" segment increased by 5% to $122.2 million, but Adjusted EBITDA decreased by 6% to $29.6 million[111]. Expenses and Cost Management - Cost of sales decreased to $349.5 million, or 50.4% of total revenues, down from $378.9 million, or 53.3% of total revenues, for the same period last year[91]. - Selling, marketing, and administrative expenses decreased by 8.6% to $187.0 million, primarily due to cost-savings initiatives[93]. - Research and development expenses decreased by 10.1% to $53.2 million, also attributed to cost-savings initiatives[94]. - Integration-related costs decreased to $16.1 million from $22.6 million in the prior year, reflecting lower consulting and compensation-related charges[96]. Tax and Financial Position - The effective tax rate for the three months ended March 30, 2025, was negative 44.3%, compared to an effective tax rate of 5.2% in the prior year, primarily due to operating losses in certain subsidiaries[101]. - Cash and cash equivalents increased by $28.8 million to $127.1 million as of March 30, 2025[113]. - Net cash provided by operating activities was $65.6 million for the three months ended March 30, 2025, compared to a cash outflow of $0.7 million in the same period of 2024[117]. - Capital expenditures for the three months ended March 30, 2025, were $56.2 million, primarily for manufacturing capacity expansion[116]. - The company anticipates that current cash and cash equivalents, along with cash from operations, will be sufficient to fund near-term capital and operating needs for at least the next 12 months[122]. Strategic Initiatives - The company initiated a wind-down plan for the U.S. donor screening portfolio, expected to be substantially complete by the end of 2025, contributing to revenue decline[82]. - The company expects overall demand for its products to continue to fluctuate, influenced by seasonal respiratory demands and competitive pressures[85]. - The company is focused on expanding the number of instruments placed in the field through a reagent rental model to enhance recurring revenue and cash flows[126].

Revenue Performance - Total revenue for Q1 2025 was $693 million, a decrease of 2.5% from $711 million in the prior year period, primarily due to lower COVID-19 and Donor Screening revenue[3] - Non-respiratory revenue was $573 million, flat compared to the prior year, while Labs revenue grew by 5% as reported and 7% in constant currency[5] - Total revenues for the three months ended March 30, 2025, were $692.8 million, a decrease of 2.6% compared to $711.0 million for the same period in 2024[32] - Respiratory revenues decreased by 12.7% to $119.8 million for the three months ended March 30, 2025, compared to $137.3 million for the same period in 2024[32] - Non-respiratory revenues remained relatively stable at $573.0 million, a slight decrease of 0.1% compared to $573.7 million in the prior year[32] Profitability Metrics - GAAP diluted loss per share for Q1 2025 was $0.19, significantly improved from a loss of $25.50 in the prior year period[4] - GAAP operating income for Q1 2025 was $33 million, compared to an operating loss of $1.76 billion in the prior year, with an operating margin of 5%[4] - Adjusted EBITDA for Q1 2025 was $160 million, up from $132 million in the prior year, with an adjusted EBITDA margin of 23%[6] - Adjusted net income for the three months ended March 30, 2025, was $50.2 million, or $0.74 per diluted share, compared to $29.8 million, or $0.44 per diluted share, for the same period in 2024[25] - The company reported a net loss of $12.7 million for the three months ended March 30, 2025, compared to a net loss of $1,706.0 million for the same period in 2024[30] Cash Flow and Assets - Cash provided by operating activities was $65.6 million for the three months ended March 30, 2025, compared to cash used of $0.7 million for the same period in 2024[22] - Cash, cash equivalents, and restricted cash at the end of the period increased to $127.2 million from $79.0 million at the end of the same period in 2024[22] - Total current assets increased to $1,258.2 million as of March 30, 2025, from $1,218.9 million as of December 29, 2024[20] - Total liabilities increased to $3,464.4 million as of March 30, 2025, compared to $3,439.1 million as of December 29, 2024[20] Guidance and Future Outlook - The company maintains its full-year 2025 financial guidance, expecting total revenues between $2.60 billion and $2.81 billion[7] - Adjusted diluted EPS for 2025 is projected to be between $2.07 and $2.57[7] Operational Initiatives - Integration-related charges for Q1 2025 amounted to $16 million, contributing to the overall operating expenses of $240 million, which decreased by 9%[5] - The company is focused on operational improvement initiatives to address macroenvironment challenges and enhance profitability[2]

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? QuidelOrtho (QDEL) , which belongs to the Zacks Medical - Products industry, could be a great candidate to consider.This medical diagnostics company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 94.37%.For the most recent quarter, QuidelOrtho ...

QuidelOrtho (QDEL) shares ended the last trading session 10.1% higher at $28.85. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 29.7% loss over the past four weeks.The upside can be attributed to relief-rally across global markets following the announcement of a 90-day pause on tariff hike by the United States.This medical diagnostics company is expected to post quarterly earnings of $0.61 per share in its upcomin ...

Company Overview - QuidelOrtho (QDEL) has launched the Results Manager System, aimed at streamlining diagnostic data management and improving laboratory workflow efficiency [1][2] - The system enhances connectivity by integrating test results from multiple sources, facilitating faster and more accurate decision-making [1][3] Product Features - The Results Manager System centralizes diagnostic data management, providing a unified view of patient diagnostics and reducing manual data entry, which minimizes errors [3][4] - It supports real-time quality monitoring and automates workflows with features like auto-verification, thus reducing manual effort [4] - The system is scalable and cost-effective, designed to optimize efficiency and reliability for laboratories of all sizes [4] Industry Prospects - The global in vitro diagnostics market was valued at $108.30 billion in 2024 and is projected to grow at a CAGR of 5.62% from 2025 to 2030, driven by the demand for accurate and rapid diagnostic solutions [5][6] - Key growth drivers include the rising prevalence of chronic and infectious diseases, advancements in diagnostics, and a shift towards value-based healthcare [6] Competitive Landscape - Hologic (HOLX) is expanding its diagnostic portfolio with a focus on women's health and has received CE-marking for its Affirm Contrast Biopsy Software [7] - Abbott (ABT) is innovating in infectious disease diagnostics, with recent WHO approval for its Alinity m MPXV assay for emergency use [8] - Grail (GRAL) is advancing early cancer detection through collaborations aimed at improving access to its multi-cancer early detection test [9]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-41409 QUIDELORTHO CORPORATION (Exact name of registrant as specified in its charter) De ...

Healthcare in vitro diagnostics company QuidelOrtho (QDEL 4.28%) attracted the right kind of attention from investors after posting its latest quarterly earnings report on Thursday. A rather encouraged market traded the company's shares up by more than 4% in response. That was more than good enough to top the S&P 500 index's slightly over 1% increase.Narrower-than-expected declinesQuidelOrtho's fourth-quarter and full-year results, unveiled after market close on Wednesday, showed that the company earned $70 ...

QuidelOrtho Corporation (QDEL) delivered adjusted earnings per share (EPS) of 63 cents in the fourth quarter of 2024, down 46.2% year over year. The figure, however, topped the Zacks Consensus Estimate by 14.6%.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.The adjustments include expenses related to the amortization of intangibles, and acquisition and integration costs, among others.GAAP loss per share for the quarter was $2.28 against the year-earlier EPS of 10 cents.Full-year 2024 ...

Financial Data and Key Metrics Changes - Total reported revenue in Q4 2024 was $708 million, a decrease of 4% year-over-year due to declines in COVID and flu testing revenues [10][20] - Adjusted EBITDA for Q4 2024 was $150 million, representing a 21% adjusted EBITDA margin, compared to $195 million in the prior year period [13][26] - Full year 2024 total reported revenue was $2.8 billion, including $2.3 billion in non-respiratory revenue, with adjusted diluted earnings per share at $1.85 [18][19] Business Line Data and Key Metrics Changes - Labs business, approximately 50% of total revenues, achieved 4% growth on a reported and constant currency basis, excluding COVID and non-core revenue [11] - Immunohematology business within transfusion medicine grew 4% in Q4 2024, while donor screening revenue declined by 40% [23] - Q4 respiratory revenue declined 18% year-over-year, with $44 million in COVID revenue [24] Market Data and Key Metrics Changes - Fourth quarter constant currency revenue performance was led by the "other region" (Japan, Asia Pacific, Latin America), which grew 13% [20] - China grew 11%, driven by strong labs performance, partially offset by softness in cardiac point of care products [21] - North America declined by 11% due to anticipated declines in respiratory revenue and donor screening revenue [22] Company Strategy and Development Direction - The company is focusing on improving its cost structure and prioritizing high-impact opportunities to drive profitable growth [8][14] - Key priorities include enhancing customer experience, executing on high-impact programs, and driving sustainable growth through improved R&D productivity [13] - The company plans to implement cost reduction initiatives, targeting $100 million in annualized savings, with $50 million expected in the first half of 2025 [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in the second half of 2024 and expects continued momentum into 2025 [17][30] - The company anticipates full year 2025 total reported revenue between $2.6 billion and $2.81 billion, with adjusted EBITDA between $575 million and $615 million [31] - Management noted that the risk of additional VBP pressure in China has largely passed, but competitive intensity has increased [48][82] Other Important Information - The company finished Q4 2024 with $98 million in cash and $198 million in borrowings on its $800 million revolver [28] - Adjusted free cash flow for Q4 2024 was $68 million, representing 45% of adjusted EBITDA [29] - The effective adjusted income tax rate for 2024 was 24% [27] Q&A Session Summary Question: Guidance on free cash flow conversion - Management acknowledged that free cash flow conversion is expected to improve to 25% to 30% of adjusted EBITDA in 2025, with a long-term goal of reaching at least 50% [44] Question: Update on the China region and pricing - Management indicated that the risk of additional VBP pressure has largely passed for 2025, with competitive intensity increasing but no significant actions expected [48][82] Question: Cost savings and EBITDA drivers - Management highlighted that $50 million of cost savings from previously announced initiatives will benefit the first half of 2025, with additional savings expected from procurement [55] Question: Respiratory revenue expectations - Management expects respiratory revenue to grow in the low single digits for 2024 and 2025, with a focus on flu, RSV, and strep [59] Question: Long-term margin expansion - Management targets adjusted EBITDA margins greater than 25% over the next two to three years, with progress expected as direct procurement savings materialize [87] Question: Timing for Savanna trials - Management confirmed that Savanna trials started in January, with expectations for market entry later in the year if trials are successful [98] Question: Donor screening revenue guidance - Management expects U.S. donor screening revenue to be $40 million to $50 million in 2025, down significantly from 2024 [100]

QuidelOrtho (QDEL) came out with quarterly earnings of $0.63 per share, beating the Zacks Consensus Estimate of $0.55 per share. This compares to earnings of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.55%. A quarter ago, it was expected that this medical diagnostics company would post earnings of $0.31 per share when it actually produced earnings of $0.85, delivering a surprise of 174.19%.Over the last four quart ...